These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 11157476)

  • 1. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model.
    Moskowitz CH; Nimer SD; Zelenetz AD; Trippett T; Hedrick EE; Filippa DA; Louie D; Gonzales M; Walits J; Coady-Lyons N; Qin J; Frank R; Bertino JR; Goy A; Noy A; O'Brien JP; Straus D; Portlock CS; Yahalom J
    Blood; 2001 Feb; 97(3):616-23. PubMed ID: 11157476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ifosfamide, idarubicin, and etoposide in relapsed/refractory Hodgkin disease or non-Hodgkin lymphoma: a salvage regimen with high response rates before autologous stem cell transplantation.
    Oyan B; Koc Y; Ozdemir E; Kars A; Turker A; Tekuzman G; Kansu E
    Biol Blood Marrow Transplant; 2005 Sep; 11(9):688-97. PubMed ID: 16125639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Double high-dose therapy for Hodgkin's disease with dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP) prior to high-dose melphalan and autologous stem cell transplantation.
    Stewart DA; Guo D; Glück S; Morris D; Chaudhry A; deMetz C; Klassen J; Brown CB; Russell JA
    Bone Marrow Transplant; 2000 Aug; 26(4):383-8. PubMed ID: 10982284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High dose chemoradiotherapy and ASCT may overcome the prognostic importance of biologic markers in relapsed/refractory Hodgkin lymphoma.
    Persky DO; Moskowitz CH; Filatov A; Saxena R; Cui H; Teruya-Feldstein J
    Appl Immunohistochem Mol Morphol; 2010 Jan; 18(1):35-40. PubMed ID: 19701081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DexaBEAM versus ICE salvage regimen prior to autologous transplantation for relapsed or refractory aggressive peripheral T cell lymphoma: a retrospective evaluation of parallel patient cohorts of one center.
    Mikesch JH; Kuhlmann M; Demant A; Krug U; Thoennissen GB; Schmidt E; Kessler T; Schliemann C; Pohlen M; Mohr M; Evers G; Köhler G; Wessling J; Mesters R; Müller-Tidow C; Berdel WE; Thoennissen NH
    Ann Hematol; 2013 Aug; 92(8):1041-8. PubMed ID: 23532626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.
    Abali H; Urün Y; Oksüzoğlu B; Budakoğlu B; Yildirim N; Güler T; Ozet G; Zengin N
    Cancer Invest; 2008 May; 26(4):401-6. PubMed ID: 18443961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging.
    Moskowitz CH; Yahalom J; Zelenetz AD; Zhang Z; Filippa D; Teruya-Feldstein J; Kewalramani T; Moskowitz AJ; Rice RD; Maragulia J; Vanak J; Trippett T; Hamlin P; Horowitz S; Noy A; O'Connor OA; Portlock C; Straus D; Nimer SD
    Br J Haematol; 2010 Mar; 148(6):890-7. PubMed ID: 20085577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose cyclophosphamide, carmustine (BCNU), and etoposide (VP16-213) with or without cisplatin (CBV +/- P) and autologous transplantation for patients with Hodgkin's disease who fail to enter a complete remission after combination chemotherapy.
    Reece DE; Barnett MJ; Shepherd JD; Hogge DE; Klasa RJ; Nantel SH; Sutherland HJ; Klingemann HG; Fairey RN; Voss NJ
    Blood; 1995 Jul; 86(2):451-6. PubMed ID: 7541661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment outcome in children and adolescents with relapsed Hodgkin lymphoma--results of the UK HD3 relapse treatment strategy.
    Shankar A; Hayward J; Kirkwood A; McCarthy K; Hewitt M; Morland B; Daw S
    Br J Haematol; 2014 May; 165(4):534-44. PubMed ID: 24754633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose chemotherapy with or without total body irradiation followed by autologous bone marrow and/or peripheral blood stem cell transplantation for patients with relapsed and refractory Hodgkin's disease: results in 85 patients with analysis of prognostic factors.
    Nademanee A; O'Donnell MR; Snyder DS; Schmidt GM; Parker PM; Stein AS; Smith EP; Molina A; Stepan DE; Somlo G
    Blood; 1995 Mar; 85(5):1381-90. PubMed ID: 7858268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Favorable outcome of patients with relapsed or refractory Hodgkin's disease treated with high-dose chemotherapy and stem cell rescue at the time of maximal response to conventional salvage therapy (Dex-BEAM).
    Josting A; Kàtay I; Rueffer U; Winter S; Tesch H; Engert A; Diehl V; Wickramanayake PD
    Ann Oncol; 1998 Mar; 9(3):289-95. PubMed ID: 9602263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study.
    Josting A; Sieniawski M; Glossmann JP; Staak O; Nogova L; Peters N; Mapara M; Dörken B; Ko Y; Metzner B; Kisro J; Diehl V; Engert A
    Ann Oncol; 2005 Aug; 16(8):1359-65. PubMed ID: 15939712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accelerated Total Lymphoid Irradiation-containing Salvage Regimen for Patients With Refractory and Relapsed Hodgkin Lymphoma: 20 Years of Experience.
    Rimner A; Lovie S; Hsu M; Chelius M; Zhang Z; Chau K; Moskowitz AJ; Matasar M; Moskowitz CH; Yahalom J
    Int J Radiat Oncol Biol Phys; 2017 Apr; 97(5):1066-1076. PubMed ID: 28332991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma: an intention-to-treat analysis.
    Kewalramani T; Zelenetz AD; Hedrick EE; Donnelly GB; Hunte S; Priovolos AC; Qin J; Lyons NC; Yahalom J; Nimer SD; Moskowitz CH
    Blood; 2000 Oct; 96(7):2399-404. PubMed ID: 11001890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose therapy and autologous stem cell transplantation in relapsed and refractory Hodgkin's disease: outcome based on a prognostic model.
    Qazilbash MH; Devetten MP; Abraham J; Lynch JP; Beall CL; Auber M; Weisenborn R; Bunner P; Ericson SG
    Acta Haematol; 2003; 110(4):173-8. PubMed ID: 14663160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma.
    Moskowitz AJ; Yahalom J; Kewalramani T; Maragulia JC; Vanak JM; Zelenetz AD; Moskowitz CH
    Blood; 2010 Dec; 116(23):4934-7. PubMed ID: 20733154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose chemotherapy and autologous peripheral blood progenitor cell transplant for the treatment of Hodgkin's disease.
    Weaver CH; Schwartzberg L; Li W; Hazelton B; West W
    Bone Marrow Transplant; 1996 May; 17(5):715-21. PubMed ID: 8733687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study.
    Moskowitz AJ; Schöder H; Yahalom J; McCall SJ; Fox SY; Gerecitano J; Grewal R; Hamlin PA; Horwitz S; Kobos R; Kumar A; Matasar M; Noy A; Palomba ML; Perales MA; Portlock CS; Sauter C; Shukla N; Steinherz P; Straus D; Trippett T; Younes A; Zelenetz A; Moskowitz CH
    Lancet Oncol; 2015 Mar; 16(3):284-92. PubMed ID: 25683846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term follow-up in patients treated with Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease.
    Martín A; Fernández-Jiménez MC; Caballero MD; Canales MA; Pérez-Simón JA; García de Bustos J; Vázquez L; Hernández-Navarro F; San Miguel JF
    Br J Haematol; 2001 Apr; 113(1):161-71. PubMed ID: 11328296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.